There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.
Research In Motion
Amicus Therapeutics lived up to its ticker symbol, folding under pressure after disclosing disappointing clinical trial results. The company's treatment for Fabry disease, a genetic disorder affecting thousands of people worldwide, failed to meet its primary endpoint.
Research In Motion tumbled on Friday after reporting its latest quarterly results. The report itself wasn't that bad. What spooked investors was a warning that tweaked rates on service fees for next year's BlackBerry 10 phones will pressure margins.
Clearwire was one of the market's biggest winners two weeks ago, when Sprint Nextel cut a deal to acquire its WiMAX network partner. Shares of Clearwire slipped this week after Sprint Nextel didn't sweeten its offer as much as some were expecting.
Silvercorp slipped after the Vancouver-based silver producer had an uninspiring update on its operations for the Ying Mining District in China.
Amarin appears to be on a crash diet. Shares of the promising diet-drug company have fallen for seven consecutive trading days. You often don't see that kind of downturn with any kind of bounce. Amarin's been reeling since announcing plans to take on $100 million in debt financing to build up its sales force to market its triglyceride-lowering drug on its own. Speculators were betting on a Big Pharma buyout, but that seems less likely now.
Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.
The article 5 of Last Week's Biggest Losers originally appeared on Fool.com.
Longtime Fool contributor Rick Aristotle Munarriz and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.